Cadila Healthcare aims to double US business to $1 billion in 3 years

Pharma major to launch 100 new products; Moraiya facility slated to come out of US FDA woes

Ahmedabad-based pharmaceutical major Cadila Healthcare Ltd (also known as Zydus Cadila), which draws 40 per cent of its revenues from the US market, aims to double its US base business, which currently stands at $553 million, over the next three years by launching approximately 100 products. 

It has 197 abbreviated new drug approvals (ANDAs) pending approval in the US market. 

A senior official of the company said on grounds of anonymity that Zydus was bullish on its US business and projected that its share in the company's overall revenues would rise as well. "We have a good pipeline for the US